Tests AZD1163 in adults with moderately to severely active rheumatoid arthritis
Tests the drug AZD1163 against a placebo in adults with active rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Key facts
- Where
- CABA, Ciudad de Buenos Aires, Córdoba, San Isidro, and San Miguel de Tucumán, ArgentinaSee the 5 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately-to-severely active rheumatoid arthritis (RA) to test the drug AZD1163 against placebo.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- RA diagnosed in adulthood (2010 ACR/EULAR criteria) for at least 12 weeks, with moderately-to-severely active disease: at least 6 swollen joints, at least 6 tender joints, and CRP above the upper limit of normal.
- Earlier treatment
- Must have had an inadequate response, loss of response or intolerance to at least one csDMARD and/or at least one and at most 2 TNFi. Must have had at least 12 weeks of treatment, stable for at least 4 weeks, on a csDMARD and/or SC TNFi before randomisation. Must not have had biologic DMARDs (except TNFi) or targeted synthetic DMARDs.
- Biomarker or test result
- Positive ACPA at screening.
Main reasons for not taking part
- Another autoimmune or other condition that could confuse the RA diagnosis (RA with secondary Sjogren's disease can join)
- Has received or plans to receive biologic DMARDs other than TNFi
- Has received or plans to receive targeted synthetic DMARDs
Read by machine on 9 November 2026.
Where in Argentina
- CABAHospital not named in the registryTaking people
- Ciudad de Buenos AiresHospital not named in the registryTaking people
- CórdobaHospital not named in the registryTaking people
- San IsidroHospital not named in the registryTaking people
- San Miguel de TucumánHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07276581
- Record updated
- 9 October 2026
- Original description
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.Read full original descriptionShow less
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Inclusion; Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening; Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal; Have a positive ACPA at screening; A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi; A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation; Exclusion; History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible; Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.